Life Sciences Archive » February, 2022

Life Sciences - February, 2022

297 articles

• Endo, Arnold & Porter Opioid Discovery Called 'Truly Awful'
• Mylan Inks $264M Deal Ending EpiPen Class Price-Hike Suit
• DHS Urges Justices To Pass On $30M Terminated Contract
• The Battle To Confirm Ketanji Brown Jackson
• Moderna Faces Patent Suit Over Its COVID-19 Vaccine
• Smith & Nephew Gets Claims Trimmed In Hip Implant MDL
• GOP Sens. Ask HHS To Nix 'Toxic' Bid To Seize Cancer Drug IP
• Cravath, Goodwin Pilot Viatris' Up To $3.34B Biosimilars Deal
• Opana Buyers Want Pay-For-Delay Trial Split In 3
• Norton Rose Grabs IP Team From Haynes And Boone
• Bankrupt Stem Cell Biz To Pay $3.65M In Class Settlement
• Bankruptcy Is Optimal Venue For Mass Tort Cases
• Winston & Strawn Snags NY Real Estate Partner
• Party Leaders Vow Open Minds For New High Court Pick
• DOJ Has Few Allies, Many Foes In High Court Opioid Brawl
• How Judge Jackson Beat Out Competition For High Court Nod
• Why Ketanji Brown Jackson Honored This Historic Judge
• NJ Judge Scraps Claims In 2 Horizon Drug Patents
• 1st Circ. Judge Selya Says Jackson Will Be 'Balanced'
• Cannabis Bill Roundup: Legalization Bids Advance In SD, Md.
• Zetia Buyers Get Narrow Market In Generic-Delay Suit
• 6th Circ. Won't Revive Ex-P&G Worker's Benefits Suit
• Litigator Makes Move From Bartlit Beck To Winston & Strawn
• Stericycle Takes $81M Hit On Bribery Deal With DOJ, SEC
• Biden's Supreme Court Pick Was Star Debater In Miami
• The Key To Turning Solid Briefs Into Winning Briefs
• What's At Stake In Doctors' Opioid Liability Case In High Court
• Generic-Drug Maker Takes Novartis Battle To Full Fed. Circ.
• ABI Panelists, US Chamber Support Ch. 11 3rd-Party Releases
• J&J, Drug Distributors' $26B Opioid Settlement Is Finalized
• Biohaven Inks Up To $1.24B Deal For Epilepsy Drug Biz
• Jones Day Hires International Arbitration Pro From Dentons
• J&J Talc Unit's Ch. 11 Case Allowed To Go Forward
• 6 Judge Ketanji Brown Jackson Opinions To Read Now
• Biden Nominates Judge Ketanji Brown Jackson To High Court
• DuPont Spinoff Must Face Investors' Enviro Liabilities Suit
• Anthem BCBS Gets Trans Worker's Discrimination Suit Tossed
• FDA Rips CytoDyn's 'Concerning' COVID Video
• FWS Sued For Delayed Review Of Pesticides' Species Impacts
• US Again Places 2nd In Global Patent Protection
• IP Forecast: PayPal Looks To Halt Inventor's Patent Campaign
• Juul Deal Was Not Why Altria Closed Rival, FTC Judge Finds
• Teligent Says Stalled Plan Talks Make Liquidation Best Option
• Steps For Universities As DOJ Shifts Foreign Influence Policy
• FDA Commits To Compounding Drug Rulemaking
• Health Workers Can't Get Freeze On NY Vaccine Mandate
• UnitedHealth Unit Pays $5.8M To End Mass. Drug Price Probe
• Ballard Spahr M&A Leader Sees Bright Future For Deal-Making
• Allen & Overy To Launch In Boston With Ex-Goodwin Attys
• Medtronic Can't Shake Illegal Kickback Suit
• Real Estate Rumors: City National, Bullfinch, Benjamin Group
• Racehorse Trainer Snared In Doping Scandal Gets 3 Years
• Telehealth Fraud Not An Easy FCA Target, DOJ Attys Say
• Trade Org Urges Gov't Action On Hemp-Derived Intoxicants
• What To Know About The Growing PFAS Litigation
• Pfizer Drops Case Alleging Ex-Employee Stole Pharma Data
• USPTO Says Arthrex Patent Do-Over Bid Could Paralyze Gov't
• AstraZeneca Says Patent Office's Fintiv Rule Unlike Any Other
• Shkreli Banned As A Public Co. Leader After Pharma Blacklist
• Philip Morris Attys Nab $575K Fee In Extinguished E-Cig Suit
• Tainted Products Force Hand Sanitizer Maker Into Ch. 11
• Walgreens, Drugmakers Can't Get Stay In Opioid Bellwether
• After West Texas Ruling, Patenting AI Could Be More Nuanced
• Mallinckrodt Wins Approval Of $66M Securities Deal
• Baxter Settles SEC Charges Over Forex Accounting Controls
• Valeant Judge OKs $23M To End 'Secret' Pharmacy RICO Suits
• Cameras, Cancer Drug And Soup Dodge Justices' IP Scrutiny
• Maker Of Recalled COVID-19 Tests Accused Of False Labeling
• FDA Urged To Rethink CBD Status In New Trade Org. Petition
• Advocacy Group Criticizes Pfizer's COVID-19 Pill IP Bids
• Groups Say FERC's Utility Accounting Rules Need Changes
• Importer Nabs Tariff Classification Win For Medical Packaging
• Stryker Must Face FCA Claim In Medical Device Fraud Suit
• Charities Ensnared In NJ Antitrust Suit Over Cancer Drugs
• Orrick Adds Life Sciences Atty From Morgan Lewis
• Kirkland Snags $200K Fees From NY In Opioid Surcharge Suit
• Irish High Court Asks ECJ For Guidance On Drug Patent
• NJ Medical Pot Hopefuls Say Agency Snubbed Court Ruling
• Cannabis Bill Roundup: Legalization Bids In The Heartland
• J&J Talc Unit Says Ch. 11 Only Recovery Option For Claimants
• Grassley Squeezes Feds For Info On STEM Work Program
• Perrigo Investors' Attys Score $11.5M From Tax Bill Settlement
• Prenatal Defect Test Maker Hit With Suit Over False Positives
• Buyers Hit Abbott Labs With Baby Food Suit Amid FDA Probe
• Walter Dellinger's Little-Known, Outsize Impact On Legal Aid
• Blood Plasma Cos. Can't Revive Visa Suit, D.C. Circuit Told
• Health Hires: Horizon Therapeutics, Zynerba
• Trainer In Horse Doping Scheme Deserves 3 Years, Feds Say
• Sacklers Offer Another $1.6B For Purdue Ch. 11 Settlement
• Celanese Pays $11B For DuPont Unit In Deal Led By 3 Firms
• Talc Claimants Say J&J Unit's Ch. 11 Benefits Parent Co. Only
• IP Forecast: Activision Blizzard Set For Trial Over Data Patent
• CBD Co. Mostly Escapes Claims By Ex-Stratton Oakmont Rep
• J&J Units Aim To Hit Brakes On Generic Schizophrenia Drug
• Attys From Four Firms Named To Co-Lead Philips CPAP MDL
• How Fintiv Stipulations Affect IPR Institution, By The Numbers
• Moderna's South African Patent Filings Raise Activists' Alarms
• Nurse, Marine Reservist Charged With Selling Fake Vax Cards
• Why I'll Miss Arguing Before Justice Breyer
• Amid Historic Spending, Congress Should Strengthen FCA
• Judge Axes HHS Letter Over AstraZeneca Discount Dodging
• Australian Condom Co. Takes 'Naked' TM Fight To Court
• Perkins Coie Hires Ex-Jones Day Patent Atty & Inventor
• 5th Circ. Backs Workers Fighting United Airlines Vax Mandate
• NY Cannabis Regulators Approve New Medical Pot Rules
• Life Sciences Group Of The Year: Williams & Connolly
• Purdue Gets OK For 2-Week Opioid Suit Freeze Extension
• Invisalign Must Face Fed Antitrust Claims, Some State Claims
• Endo Urges Opioid Judge's DQ For 'Egregious' Ethics Lapses
• Pfizer Prevails In Proposed Class Action Over Chantix Recall
• '150 Billion Pills' Gaffe Imperils NY AG's Opioid Win Over Teva
• Tesla, Comcast, Dell, Mylan Join Tech Cos. In Fighting Fintiv
• Westco Says Workers Not Harmed By 'Secret' Pension Plan
• Texas Sues Biden Over Air Travel Mask Mandate
• Boston Firefighters Say 3M, DuPont Hid PFAS Cancer Risk
• Ex-Pharma CEO Wants Landmark Opioid Conviction Tossed
• Calif. Gets Pay-For-Delay Ban Partially Revived
• Air Force Can't Make Unvaccinated Ga. Officer Retire
• What Cos. Can Learn From The 2021 FCA Recovery Statistics
• More Antitrust Scrutiny Of Pharma Won't Help Patient Health
• Austrian Pharma Co.'s €142M Award Nixed In Germany
• Cities, Tribes, Schools Fight Toss Of McKinsey Opioid MDL
• Monsanto, BASF Say $75M Dicamba Verdict Misplaced Blame
• DOJ Pans Glenmark 'Fishing Expedition' For Grand Jury Docs
• Recent Rulings Show Lawyer Criticism Of Judges Is Perilous
• Haynes And Boone Nabs Oblon McClelland Vet In DC
• Ch. 11 For J&J Talc Unit Only Wise Choice, Top Lawyer Says
• Med Co. Trims But Can't Ax Spinal Implant Patent Suit
• Fed. Circ. Forum Selection Ruling Serves As 'Cautionary Tale'
• Alexion, Chugai Settle Blood Drug IP Row On Day Of Trial
• Defiant Priest May Face Ban After Verdict In SEC Fraud Case
• Takeaways From DOJ Fraud Section's 2021 Year In Review
• Fed. Circ. Says 'Ad Hoc' Group Can't Revive Amarin Drug IP
• Genesis Unicorn SPAC Leads 2 IPOs That Raise $135M Total
• CVS Wants Consolidated Drug Pricing Suit In Arbitration
• Medline Seeks End To Hartford's Libel Suit Coverage Fight
• Life Sciences Group Of The Year: Paul Weiss
• Breyer's Role In Courthouse Design Sets A Judicial Template
• Shearman & Sterling Adds Arbitration Pro From Jones Day
• In Close Vote, Senate Confirms Califf To Head FDA
• Endo Opioid Saga 'Like A John Grisham Movie,' Judge Says
• Talc Claimants Argue Bad Faith In J&J Unit's Ch. 11 Trial
• Lab Owners Must Face $24M Medicaid Overpayment Claims
• Contractor, Investors Reach $3.3M Deal In COVID Tests Suit
• Okla. Rolled Out Medical Pot Too Quickly, Watchdog Finds
• Ark. Pot Cos. Say State's New Rules Are Unconstitutional
• Mallinckrodt Seeks Last Extension Of Ch. 11 Acthar Suit Pause
• Expect Aggressive Life Sciences Enforcement In 2022
• All But 2 Claims Trimmed In Pa. Pelvic Mesh Case
• Pfizer Hits Teva With Suit Over Arthritis Drug Patent
• Bioness Stockholders Challenge $110M Sale To Bioventus
• California Biotech Co. Appoints 1st General Counsel
• Pa. AG Says Philadelphia Vaccine Nonprofit Must Dissolve
• Life Sciences Group Of The Year: Gibson Dunn
• 5 Key Details As Endo Is Rocked Again By Opioid Default
• FDA Won't OK Pfizer's Under 5 Vax Until 3-Shot Study Is Done
• Taiwanese Pharma Co. Says €142M Award Can't Be Enforced
• Fed. Circ. Upholds J&J's Win In Surgical Tool IP Fight
• Cannabis Bill Roundup: A Cure For Hemp's THC Headaches?
• Fed. Circ. Doubts 'Ad Hoc' Group Can Revive Amarin Drug IP
• Sharply Split Full Fed. Circ. Won't Eye Skinny Label Ruling
• FTC No Longer Pressing For Caris Docs In Illumina Case
• Health Hires: Reed Smith, McGuireWoods
• Sober Home's Medical Chief Convicted Of $110M Billing Fraud
• Law Professors Say J&J Talc Ch. 11 Is Shielding Assets
• Shackelford Scoops Up More Winstead Attys In Texas
• Taxation With Representation: Kirkland, Dechert, Gibson Dunn
• Life Sciences Group Of The Year: Covington
• Endo Hit With New Default Ruling In Opioid Discovery Debacle
• Walgreens OK'd To Pursue Crowell & Moring Breach Claims
• Wash. Lays Out $38B Opioid Abatement Plan To Trial Judge
• Astellas Workers Win Class Cert. In Suit Over 401(k) Losses
• J&J Unit Says Ch. 11 Is Best Response To Talc Suit 'Tsunami'
• IP Forecast: 9th Circ. To Hear Copyright Row With Shyamalan
• Fla. Clinics Can't Ditch Gilead's HIV Drug Charity Scam Claims
• 5th Circ. Grants New Trial Over Sanofi Chemo Drug
• NJ Town Violated Civil Rights In Blocking Development
• J&J Can't Be Allowed To Dodge Civil Justice With Bankruptcy
• Fed. Circ. Axes Inventor's $1.25M IP Win Under On-Sale Bar
• Life Sciences SPAC Pulls Plans For $200M IPO
• Split Fed. Circ. Won't Restore 4 Narcan Patents
• 3M Wants High Court Look At Surgical Blanket Expert Ruling
• Clifford Chance, Kirkland Rep £1.9B PE Deal For Informa Unit
• Boston Hospitals Say Vax Rule Must Survive 1st Circ. Review
• Drugmaker Loses Suit Over Clinical Trial For Heart Medicine
• Split 5th Circ. Won't Stay Block Of Fed. Worker Vax Mandate
• Texas Wants National Guard Vaccine Mandate Halted
• Racehorse Trainers, Vet Can't Dump Doping Scheme Charges
• Zetia Buyers Defend Class Cert. As 'Common Business Sense'
• Suit Says Aetna's Fertility Treatment Policy Is Discriminatory
• NY Judge OKs Canadian Entities' Late Purdue Ch. 11 Appeal
• Medtronic Can't Ditch All Claims In Faulty Pacemaker Suit
• BigLaw Must Nix All-Or-Nothing Work Model To Retain Talent
• Cooperator In Meningitis Outbreak Case Gets Time Served
• New FCA Stats Fuel Debate Over Health Enforcement Fixation
• Feds Fight Alford Plea For Ex-Prof Accused Of Insider Trading
• Maine's Pot Residency Rule Unconstitutional, 1st Circ. Told
• Opioid Crisis In Wash. State 'Unique,' Judge Told
• Del. Judge Bars Trustee Toss Of Fecal Test Firm's Ch. 7 Docs
• Lost Theranos Data 'Paints Picture Of Deception,' Judge Says
• Senators Hear Possible Solutions To 'Texas Two-Step' Issues
• FSD Pharma Says Delaware Suit Belongs In Ontario
• FTC Gets More Time To Review Pfizer's $6.7B Arena Deal
• Fed. Circ. Says Forum Selection Clauses Can Bar PTAB Fights
• Sun Pharma, Lupin Agree To Drop Eye Pain Patent Dispute
• Canadian Entities Seek Late Appeal In Purdue Ch. 11 Case
• Biogen Hid Issues With Alzheimer's Drug, Investor Suit Claims
• Key Players In Boy Scouts Ch. 11 Attack Nondebtor Releases
• Important Product Liability Practice Trends To Watch In 2022
• Biden's Supreme Court Nominee Should Have 5 Key Qualities
• Rosen Law Firm Nabs Lead In Biotech Investor's Drug Row
• Teligent Lender Slams Creditor Group Bid To Claw Back Cash
• 1st Circ. Spots 'Gap' In Cancer-Drug Suit Against Karyopharm
• Ex-Spine Doc Owes $13M To Women Over Faulty Surgeries
• Align, 3Shape Ink IP, Antitrust Deal Over Clear Braces
• Calif. Lawmakers OK More Paid COVID Leave For Workers
• J&J Drops Bid To Block Reuters Story As Attys Trade Barbs
• Service Members Defend Challenge To Vax Approval, Mandate
• Generics Co. Accuses Ex-Exec Of Swiping Trade Secrets
• PhRMA Backs AstraZeneca In Bid For Fed. Circ. Redo
• FDA Probing Possible Death Risk Of Lymphoma Drug
• Investors Late Over AbbVie's Failed Shire Deal, Court Says
• SEC Is Pushing Boundaries In Insider Trading Enforcement
• Texas Strikes $225M Deal With Teva Over Opioid Crisis
• AstraZeneca, Merck Want Calquence Generics Halted
• Law360 Seeks Members For Its 2022 Editorial Boards
• Using 3rd-Party Releases In Chapter 11 After Court Pushback
• Flint Residents' Attys Awarded $39.6M As Part Of Water Deal
• Ex-Theranos Exec Seeks To Block Holmes Trial Evidence
• Reuters Says J&J Too Late To Nix Story Over Atty Leak Claim
• Belcher Must Cover Hospira's Legal Fees In Patent Fight
• After Patent Drama, FDA OKs Generic Restasis
• Anesthesiology Group Puts To Rest Drugmaker's Libel Suit
• UnitedHealth Units Beat ERISA Drug Overcharge Claim
• PTAB Judge Grills UC On Evidence It Invented CRISPR First
• Shkreli's Lifetime Pharma Ban Upheld
• Cadwalader's Corporate Group Nabs Investment Firm Ex-GC
• China's Expanded Data Clampdown Rankles US Lawyers
• EU Suspends Deadline For ​​​​​​​Illumina's $8B Grail Deal
• Wilson Sonsini-Led Biotech Firm Rallies After $124M IPO
• Final Approval In Glumetza Antitrust Deal Gives Attys $50M
• 2 Recent Decisions Highlight Ambiguity As FCA Defense
• Ex-NECC Execs Seek New Trial After Revived Convictions
• Feds Say J&J Talc Trust Can't Exclude Medicare Claims
• Purdue Asks For New Extension On Opioid Suit Freeze
• Pharma Co. Can't Escape Most Of Fluoride False Ad Suit
• Philly, Pittsburgh DAs Lose Bid To Stop Opioid Settlement
• Mallinckrodt Ch. 11 Plan Gets Green Light From Del. Court
• J&J Says Talc Plaintiff Attys Fed Confidential Docs To Reuters
• Opioid Trial In Wash. State Briefly Interrupted For Evacuation
• Calif. Judge Unpersuaded To Nix Drugmakers' Opioid Trial Win
• Ex-UChicago Prof Seeks Alford Plea Over Insider Trades
• IP Forecast: 11th Circ. To Eye Biz's $20M Trade Secrets Loss
• Pharma Group Wants EU On Watchlist For Weakening IP
• Scholar Briefs OK'd In J&J Talc Unit's Ch. 11 Dismissal Bid
• Fed. Circ. Affirms Preliminary Injunction In Eye Device IP Row
• Upcoming Rulings Key To Defining PREP Act Protections
• CMA Issues £35M In Fines For Alleged Drug Supply Pact
• Lifetime Ban For Shkreli Means Lifetime Ban, FTC Says
• Asbestos Suit Returns To NJ State Court After Boeing's Exit
• Deals Rumor Mill: Novartis, Cedar Fair, IVI-RMA
• Key Trade Secret Developments Of 2021: Part 2
• Ex-Novartis Exec Didn't Back Retaliation Suit, NJ Court Told
• Mississippi Legalizes Medical Pot After Governor's Signature
• BCBS Unit's $28M Shkreli Deal Poised For Initial OK
• Drug Distributor Stymied On FDA Topics In Wash. Trial Cross
• Hawaiian Airlines Workers Can't Block Vaccine Mandate
• Ex-Execs Say Ch. 7 Trustee Can't Drop Amazon Doc Storage
• Tillis Asks FDA, USPTO To Vet Reports By Drug Patent Critics
• Indivior Again Loses Bid To DQ Bankrupt Suboxone Plaintiff
• Glenmark Wants Grand Jury Evidence In Price-Fixing Case
• Product Trainer Wants Out Of $40M Pot Farm Fire Suit
• Chancery Taps 4 Firms To Lead Emergent Investor Suits
• JPML Sends False Ad Suits Over Sleep Device Cleaners To Pa.
• China Patent Ruling Highlights Anti-Monopoly Law's Reach
• Biden Nominates Michigan District Judge To 6th Circ.
• Ex-Drug Co-Op CEO Convicted In Landmark Opioid Case
• Pfizer Says Ex-Execs Swiped Data For Rival Drug Startups
• The Flaws In The Traditional Approach To Hiring A Law Firm
• Taxotere Eye Damage Suits Consolidated In Louisiana MDL
• Steptoe Adds White Collar Expert To San Francisco Office
• Gerber Accused Of Cutting Anti-Competitive Deal With Perrigo
• Gilead Pays ViiV $1.25B Plus Royalties To End HIV Patent Suit
• Novartis Ducks Regeneron's Antitrust Countersuit To IP Fight
• How Rx Drugs Become Illegal Street Sales Murky, Judge Told
• At Fed. Circ., Novartis Rips Amgen's 'Patent Estate'
• Shkreli Fights Scope Of Pharma Industry Ban
• Law Firms Weathered Frosty January As IPO Activity Slowed
• DOJ Recovers $5.6B In 2021 For 2nd-Highest FCA Haul
• Pfizer Wants FDA's Approval Of COVID Vax For Kids Under 5
• CBD Co. Inks $712K Deal To End Investors' Securities Suit
• ThermoLife Told To Take Injunction Stay Bid Up With Albright
• Roche Unit's Cancer Treatments Draw UPenn Patent Suit
• Purdue Closing In On New Ch. 11 Deal With Sackler Family
• What Pa. Procedure Rule Change Means For 'Snap Removals'
• Ex-Univar Executive Loses Push For Severance Pay
• Tribes Reach $590M Opioids Deal With J&J, Distributors